Current AAV-mediated gene therapy in sensorineural hearing loss

Area of Science:

• Otorhinolaryngology
• Regenerative Medicine
• Gene Therapy

Background:

• Hearing loss is a growing global health issue with significant quality of life impacts.
• Pathologies involve damage to cochlear sensory cells, stria vascularis, and spiral ganglion neurons.
• Current treatments focus on regeneration, with some small molecule drugs in clinical trials.

Purpose of the Study:

• To review the concepts, strategies, and applications of gene therapy for hearing loss.
• To highlight the role of recombinant adeno-associated viruses (AAV) in hearing loss research and treatment.
• To discuss the transition of gene therapy from preclinical studies to clinical exploration.

Main Methods:

• Review of current literature on gene therapy for hearing loss.
• Focus on recombinant adeno-associated virus (AAV) vector applications.
• Analysis of therapeutic strategies and their potential.

Main Results:

• Gene therapy, particularly using AAV vectors, is a promising strategy for sensorineural hearing loss.
• AAV-mediated gene therapy is transitioning from basic research to clinical safety and efficacy studies.
• Regenerative approaches, including gene therapy, aim to repair damaged inner ear structures.

Conclusions:

• Recombinant AAV gene therapy presents a viable and advancing treatment avenue for hearing loss.
• Further research is crucial to establish the safety and therapeutic potential of gene therapy for hearing restoration.
• Gene therapy holds significant promise for treating previously intractable forms of deafness.